| Followers | 128 |
| Posts | 2150 |
| Boards Moderated | 1 |
| Alias Born | 12/27/2007 |
Wednesday, December 20, 2017 9:17:00 AM
AXSM= 2 BIG P3 READOUT THIS MONTH=$$$$$
AXSM (MC $120 M) (Cash $40 M) Shares Out 25.4 M // 7x Phase 3 programs in various indications targeting billion dollar markets ..2x Phase 3 readout expected within THIS MONTH =HUGE Upside Potential on this undiscovered low float gem .GL
Axsome Therapeutics (AXSM)
Market Cap: $120 M
Cash $40 M
Price: $4.75
Shares Out : 25.4 M ( 16+ Million shares held alone by Management & Institutions)
Presentation from mid November (see slide 36 for upcoming milestones)
http://media.corporate-ir.net/media_files/IROL/25/254022/Axsome_Presentation_13%20Nov%202017.pdf
Anticipated Near-Term Clinical Milestones
Clinical Trial Readouts:
-- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (4Q 2017)
-- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)
AXSM (MC $120 M) (Cash $40 M) Shares Out 25.4 M // 7x Phase 3 programs in various indications targeting billion dollar markets ..2x Phase 3 readout expected within THIS MONTH =HUGE Upside Potential on this undiscovered low float gem .GL
Axsome Therapeutics (AXSM)
Market Cap: $120 M
Cash $40 M
Price: $4.75
Shares Out : 25.4 M ( 16+ Million shares held alone by Management & Institutions)
Presentation from mid November (see slide 36 for upcoming milestones)
http://media.corporate-ir.net/media_files/IROL/25/254022/Axsome_Presentation_13%20Nov%202017.pdf
Anticipated Near-Term Clinical Milestones
Clinical Trial Readouts:
-- Phase 3 COAST-1 trial of AXS-02 in knee OA associated with BMLs, interim analysis (4Q 2017)
-- Phase 3 CREATE-1 trial of AXS-02 in CRPS, interim efficacy analysis (4Q 2017)
Join the InvestorsHub Community
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
